LFMD News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

LF

Mkt Cap

$113.6M

Volume

820.21K

Next Earnings

November 16th

Loading chart

LF

LFMDLifeMD, Inc. Common Stock

LFMD

Pay with—

Available Balance0.00

LF

Mkt Cap

$112.9M

Volume

820.21K

Next Earnings

November 16th

Chart Financials Earnings News About Insider Filings

AT&T Teams Up With LifeMD for Virtual Health Care: Can it Aid Shares?AT&T has partnered with LifeMD to offer complimentary virtual healthcare and pharmacy services to eligible wireless and fiber customers, waiving the $19 monthly membership fee. The benefit initially covers 29 million customers in 11 states with nationwide expansion expected in January 2027. AT&T faces competition from Verizon and T-Mobile, which are also advancing healthcare technology offerings. AT&T shares have underperformed the industry over the past year, currently holding a Zacks Rank #3 (Hold) rating.Zacks Investment Research · Sep 16, 2026

LifeMD Announces Exclusive Collaboration to Launch Direct-to-Patient Self-Pay Program for XYOSTED® (testosterone enanthate) InjectionLifeMD announced an exclusive co-marketing collaboration with Halozyme's subsidiary Antares Pharma to launch a direct-to-patient self-pay program for XYOSTED, an FDA-approved testosterone auto-injector. The program will launch in July 2026 across 37 states, offering patients virtual clinical evaluation, lab testing, and home delivery of medication at a transparent price of approximately $249 per month, addressing barriers to hypogonadism treatment.GlobeNewswire Inc. · Jun 22, 2026

Slash Your Wegovy Costs: Novo Nordisk Reveals First-Ever Subscription PlanNovo Nordisk launched a subscription program for Wegovy (semaglutide) starting March 31, 2026, offering tiered pricing to reduce costs for self-pay patients. Monthly prices range from $329 to $249 for injections (up to $1,200 annual savings) and $289 to $249 for oral versions through telehealth partners including Ro, WeightWatchers, and LifeMD, with Hims & Hers and Sesame expected to join later. The program aims to improve treatment adherence and address cost barriers.Benzinga · Mar 31, 2026

LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred StockLifeMD announced a quarterly cash dividend of $0.5546875 per share on its 8.875% Series A Cumulative Perpetual Preferred Stock, payable on April 15, 2026, to shareholders of record as of April 3, 2026.Benzinga · Mar 24, 2026

Novo Nordisk's Wegovy Weight Loss Pill Hits US Pharmacies With Lower Starting CostNovo Nordisk launched its Wegovy weight loss pill in US pharmacies in December 2025 with competitive pricing starting at $149/month for self-pay patients. The pill demonstrated 17% average weight loss versus 3% for placebo. It's available through major retailers including CVS and Costco, as well as telehealth providers. Despite the positive product launch, NVO stock remains down 35.61% over the past year and trades 8.4% below its 200-day moving average.Benzinga · Jan 5, 2026

LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred StockLifeMD, Inc. announced a cash dividend of $0.5546875 per share for holders of its 8.875% Series A Cumulative Perpetual Preferred Stock, payable on January 15, 2026. The announcement reflects the company's financial stability as a leading virtual primary care provider.GlobeNewswire Inc. · Dec 26, 2025

Novo Nordisk Leans Into Affordability Amid Rising CompetitionNovo Nordisk announced a price reduction for Wegovy and Ozempic, offering a $199/month introductory rate for new self-pay patients, and lowering the standard monthly price from $499 to $349 to improve medication accessibility.Benzinga · Nov 17, 2025

LifeMD® to Offer Market-Leading Pricing for GLP-1 Medications Wegovy® and Ozempic® in Continued Collaboration with Novo NordiskLifeMD announced lower cash-pay pricing for Wegovy and Ozempic medications at $199 per month, supporting patients paying out of pocket through its Weight Management Program in collaboration with Novo Nordisk.GlobeNewswire Inc. · Nov 17, 2025

Non-Sterile Compounding Pharmacy Market Size Expected to Reach USD 12.11 Bn by 2034The global non-sterile compounding pharmacy market is projected to grow from $5.97 billion in 2024 to $12.11 billion by 2034, driven by increasing demand for personalized medications and growing chronic diseases, with North America currently leading the market.GlobeNewswire Inc. · Oct 27, 2025

LFMD Investors Have Opportunity to Lead LifeMD, Inc. Securities Fraud Lawsuit with the Schall Law FirmThe Schall Law Firm is pursuing a class action lawsuit against LifeMD for allegedly making false and misleading statements about its competitive position and financial guidance during May-August 2025.Benzinga · Oct 27, 2025

to start trading

LF

LFMDLifeMD, Inc. Common Stock

LFMD

Pay with—

Available Balance0.00

Your PositionYou don't own any LFMD yet.

Related Tickers

Earnings